spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Paclitaxel 


 Your search returned too many results! The most recent 500 items are shown below:
 HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 13 May 2024
Laborie Unveils Positive Study Results for Optilume(R) BPH Catheter System
Devices Urology
 HSMN NewsFeed - 1 Mar 2024
Boston Scientific Receives FDA Approval for the AGENT(TM) Drug-Coated Balloon
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 27 Oct 2023
Laborie Medical Technologies Acquires Urotronic
Devices Urology Mergers & Acquisitions
 HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 May 2023
Excellent 12-Month Results from SELUTION SFA Trial Presented at JET
Devices Interventional
 HSMN NewsFeed - 13 Feb 2023
Concept Medical granted Investigational Device Exemption (IDE) approval for their Magic Touch Sirolimus Coated Balloon for the treatment of Below the Knee (BTK) Arterial Disease
Devices Interventional FDA
 HSMN NewsFeed - 28 Jun 2022
Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing
Devices Interventional Cardiology Venture Capital
 HSMN NewsFeed - 8 Oct 2021
18-Month Below-the-Knee Data with MedAlliance's SELUTION SLR(TM) Presented as Late Breaking Trial at VIVA
Devices Interventional
 HSMN NewsFeed - 27 Sep 2021
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Biopharmaceuticals Urology Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2021
Medtronic Launches Newest-Generation Drug Coated Balloon Catheter in Europe for Treatment of Coronary Artery Disease
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 8 Jul 2021
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
Biopharmaceutical Personnel
 HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Dec 2020
Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea(R) (Paclitaxel Micellar) in Europe
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 9 Nov 2020
The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start
Devices Interventional
 HSMN NewsFeed - 2 Nov 2020
Boston Scientific Receives FDA Approval for the Ranger(TM) Drug-Coated Balloon
Devices Interventional FDA Product Launch
 HSMN NewsFeed - 27 Jul 2020
AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy
Biopharmaceuticals Oncology Neurology Licensing
 HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Mar 2020
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 9 Mar 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jan 2020
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Oct 2019
World-Renowned Cancer Leader Brian Leyland-Jones Named Chairman of NED Biosystems' Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Feb 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2018
Boston Scientific Receives U.S. FDA Approval for the Eluvia(TM) Drug-Eluting Vascular Stent System
Devices Interventional FDA
 HSMN NewsFeed - 5 Sep 2018
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Aug 2018
Medtronic Announces Commercial Launch of the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon in Japan
Devices Interventional Product Launch
 HSMN NewsFeed - 3 Jul 2018
MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jun 2018
Medtronic Receives FDA Approval for 200mm & 250mm IN.PACT(TM) Admiral(TM) Drug Coated Balloons
Devices Interventional FDA
 HSMN NewsFeed - 16 Jan 2018
MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2017
Oncolytics Biotech(R) Inc. Announces FDA Fast Track Designation for REOLYSIN(R) in Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Apr 2017
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
Devices Interventional Drug Delivery
 HSMN NewsFeed - 12 Apr 2017
Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Nov 2016
Athenex and Lilly Enter Clinical Collaboration Agreement
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2016
Marina Biotech Announces Merger with IthenaPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Nov 2016
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Aug 2016
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement
Biopharmaceuticals Wound Care Mergers & Acquisitions
 HSMN NewsFeed - 20 Jul 2016
Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jul 2016
QT Vascular Receives CE Mark Clearance for Chocolate Heart(TM), a Novel Drug-Coated Coronary Balloon
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 May 2016
Boston Scientific Announces Schedule of Presentations at EuroPCR 2016
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Mar 2016
Allergan Confirms Generic Abraxane(R) Patent Challenge
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 22 Feb 2016
Boston Scientific Receives CE Mark For Eluvia(TM) Drug-Eluting Vascular Stent and Announces Initiation of New Clinical Trial
Devices Interventional Regulatory Product Launch
 HSMN NewsFeed - 8 Feb 2016
STENTYS initiates the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication
Devices Interventional Product Launch
 HSMN NewsFeed - 25 Jan 2016
Athenex Announces US FDA Allowance of the Investigation New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jan 2016
Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology Gastroenterology
 HSMN NewsFeed - 7 Jan 2016
QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2015
Advanced Catheter Therapies Receives Second FDA 510(k) Clearance on Occlusion Perfusion Catheter
Devices Interventional FDA
 HSMN NewsFeed - 3 Aug 2015
CMS Approves Add-on Payment for Lutonix(R) Drug-Coated Balloon for Inpatient Use
Devices Interventional Reimbursement
 HSMN NewsFeed - 19 Jul 2015
Sorrento Announces Departure of Mr. George Uy to become CEO of Start-up Company
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Jun 2015
CMS Further Improves Reimbursement for Lutonix DCB for Outpatient Use
Devices Interventional Reimbursement
 HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Mar 2015
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Feb 2015
CTI BioPharma Announces Independent DMC Recommendation to Continue GOG-0212 Phase 3 Study of OPAXIO(TM) as Maintenance Therapy in Ovarian Cancer, an NRG Oncology/GOG Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2014
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Oct 2014
FDA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Aug 2014
Cook Medical Enrolls First Patient in Zilver(R) PTX(R) Drug Eluting Peripheral Stent Clinical Study in China
Devices Interventional
 HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jul 2014
Boston Scientific Receives CE Mark For Agent(TM) Drug-Coated Balloon
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 22 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jul 2014
Boston Scientific Receives CE Mark For Ranger(TM) Drug-Coated Balloon
Devices Interventional Regulatory
 HSMN NewsFeed - 5 Jun 2014
Cook Medical Makes Zilver(R) PTX(R) Drug-Eluting Stent Available in Canada
Devices Interventional
 HSMN NewsFeed - 22 May 2014
Covidien Releases Two-Year Study Results Demonstrating Sustained Effectiveness of Drug-Coated Angioplasty Balloon Technology
Devices Interventional
 HSMN NewsFeed - 11 Mar 2014
Sorrento Therapeutics Appoints Mark Durand to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2014
Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jan 2014
Insys Announces Details of Product Development Pipeline
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 9 Jan 2014
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jan 2014
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jan 2014
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Nov 2013
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Oct 2013
Lorus Therapeutics Appoints New Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Oct 2013
FDA Grants Lilly's Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Sep 2013
U.S. Food and Drug Administration Approves ABRAXANE(R) in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jul 2013
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jun 2013
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2013
Angiotech announces sale of Interventional Products Business to Argon Medical Devices, Inc.
Devices Interventional Acquisitions
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Feb 2013
Verastem Files for Orphan Disease Status for VS-6063 in Mesothelioma
Biopharmaceuticals Oncology Regulatory FDA
 HSMN NewsFeed - 24 Jan 2013
Final Results of Spectranetics Study Supports Successful Use of Laser Atherectomy for Treating Patients With Peripheral In-Stent Restenosis
Devices Interventional
 HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Dec 2012
First U.S. Patient Treated Following FDA Approval of Cook Medical’s First-of-its-Kind Zilver(R) PTX(R) Drug-Eluting Peripheral Stent
Devices Interventional
 HSMN NewsFeed - 19 Nov 2012
ZYTIGA(R) Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Nov 2012
Saladax Biomedical, Inc. Appoints Mark D. Myslinski as Chief Commercial Officer
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 23 Oct 2012
The Boston Scientific PROMUS Element(TM) Platinum Chromium Stent Demonstrates Positive Outcomes in Patients with Long Coronary Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2012
Kinex Pharmaceuticals Closes First Tranche of Current Round Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Oct 2012
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2012
Cook Medical’s Zilver(R) PTX(R) Trial Shows Sustained Patency after Three Years
Devices Interventional
 HSMN NewsFeed - 2 Oct 2012
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2012
Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Aug 2012
Cook Medical’s Ongoing Zilver(R) PTX(R) Trial Data Show Higher Freedom From Target Lesion Revascularization (TLR) Rates Compared to Angioplasty and Bare Metal Stenting After Three Years
Devices Interventional
 HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2012
New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech’s Perjeta
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jun 2012
Saladax Biomedical, Inc. Appoints Kevin M. Harter as President and Chief Executive Officer
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 4 Jun 2012
Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element(TM) Plus Platinum Chromium Stent System
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2012
Cook Medical Launches First Drug-Eluting Stent in Australia to Treat Peripheral Arterial Disease (PAD)
Devices Interventional Regulatory
 HSMN NewsFeed - 18 May 2012
PROMUS Element(TM) Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
Devices Interventional Cardiology
 HSMN NewsFeed - 17 May 2012
Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent(TM) Compared to the TAXUS(R) Stent Shown in Two Clinical Trial Subgroup Analyses
Devices Interventional Cardiology
 HSMN NewsFeed - 16 May 2012
Medtronic IN.PACT Drug-Eluting Balloon Studies Show Significant Benefit of Novel Medical Device in Treating Narrowed Arteries
Devices Interventional Cardiology
 HSMN NewsFeed - 16 May 2012
BIOTRONIK's Bioabsorbable Magnesium Scaffold Continues to Show Strong Results at 12 Months With Uncompromised Device Usability
Devices Interventional Cardiology
 HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2012
Cardionovum(R) Will Launch Two Drug-Eluting Balloon (DEB) Dilatation Catheter Product Families at EuroPCR 2012
Devices Interventional Cardiology
 HSMN NewsFeed - 10 May 2012
Boston Scientific Announces Schedule For EuroPCR 2012
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Apr 2012
Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Apr 2012
Medtronic Announces Global Drug-Eluting Balloon Study
Devices Interventional
 HSMN NewsFeed - 13 Apr 2012
Medtronic Initiates Landmark U.S. Drug-Eluting Balloon Study
Devices Interventional
 HSMN NewsFeed - 1 Mar 2012
Cook Medical Receives Japanese Approval to Market Its Zilver(R) PTX(R) Drug-Eluting Stent
Devices Interventional Regulatory
 HSMN NewsFeed - 1 Mar 2012
Boston Scientific Announces Launch of PROMUS Element(TM) Platinum Chromium Stent System in Japan
Devices Regulatory Interventional Cardiology
 HSMN NewsFeed - 23 Feb 2012
Boston Scientific Receives Industry's First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 22 Feb 2012
Vascular Magnetics Raises $7 Million in Series A Financing to Advance Magnetically Targeted Drug Delivery System for Peripheral Artery Disease
Devices Drug Delivery Venture Capital
 HSMN NewsFeed - 2 Feb 2012
Spectranetics Announces Interim Results from German Study Treating Patients with Peripheral In-Stent Restenosis
Devices Interventional
 HSMN NewsFeed - 1 Feb 2012
Boston Scientific Announces First Implant and Market Launch of PROMUS Element(TM) Plus Stent System in Europe
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Jan 2012
Saladax Biomedical, Inc. Announces the Resignation of Edward L. Erickson as President and Chief Executive Officer
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 4 Nov 2011
Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Nov 2011
Bayer HealthCare's MEDRAD Interventional Business Announces Five-Year Data of Cotavance(R) Drug Eluting Balloon with Paccocath(R) Technology to be Presented at 2011 TCT
Devices Interventional
 HSMN NewsFeed - 1 Nov 2011
Boston Scientific Announces Schedule of Events at TCT Scientific Symposium
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2011
Boston Scientific Launches Promus Element™ Stent System In China
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Oct 2011
Aptus Endosystems Appoints New Board Member
Devices Interventional Personnel
 HSMN NewsFeed - 5 Oct 2011
Boston Scientific Begins Clinical Trial Enrollment for OMEGA(TM) Platinum Chromium Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 15 Jul 2011
Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2011
Breast Cancer Genomic Test Shown to Predict Patient Survival Following Adjuvant Chemotherapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 25 May 2011
Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS(R) 2.25 mm Everolimus-Eluting Coronary Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 20 May 2011
PROMUS Element Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Apr 2011
Boston Scientific Announces FDA Approval and U.S. Launch of ION Platinum Chromium Stent System
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 4 Apr 2011
Boston Scientific's Promus Element Platinum Chromium Stent System Demonstrates Comparable Safety And Effectiveness Outcomes Versus Leading Drug-Eluting Stent In Platinum Workhorse Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Apr 2011
BIOTRONIK Announces Positive 6-month Results for Pantera(R) Lux Paclitaxel Releasing Balloon
Devices Interventional Cardiology
 HSMN NewsFeed - 7 Mar 2011
Boston Scientific Announces European Approval and Launch of OMEGA Platinum Chromium Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Feb 2011
Boston Scientific Launches PROMUS(R) Element and TAXUS(R) Element Stent Systems in India
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2011
Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element Everolimus-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Jan 2011
APP Pharmaceuticals Announces Agreement with Teva Pharmaceuticals to Manufacture and Market Gemcitabine HCI for Injection
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 18 Jan 2011
Cook Medical’s Ongoing Drug-Eluting Peripheral Stent Trial Shows Consistent Outcomes Over 24 Months Compared to One-Year Data
Devices Interventional
 HSMN NewsFeed - 5 Jan 2011
TetraLogic Closes $23 Million Second Tranche of Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2010
Lilly Suspends Phase III Trial in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2010
Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Nov 2010
Paclitaxel Poliglumex (OPAXIO(R)) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2010
Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 8 Nov 2010
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Nov 2010
BIOTRONIK Announces First Patient Enrollment in the BIOLUX P-I Clinical Study Investigating Drug-Eluting Balloon Therapy for Peripheral Artery Disease
Devices Interventional
 HSMN NewsFeed - 15 Oct 2010
Celgene Completes Acquisition of Abraxis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Sep 2010
Medtronic Advances Research on Drug-Eluting Balloons for Coronary and Peripheral Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Sep 2010
Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo Bio-engineered Sirolimus Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Outstanding Two-Year Clinical Results Versus TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Sep 2010
Boston Scientific's TAXUS(R) Element Stent Demonstrates Strong Outcomes in Diabetic Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Sep 2010
Long-Term Data Show Advantages for TAXUS(R) Liberte(R) Stent in Small Vessels and Long Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Sep 2010
PROMUS(R) Element Stent Approved for Use in Diabetic and Heart Attack Patients in CE Mark Countries
Devices Regulatory Interventional Cardiology
 HSMN NewsFeed - 13 Sep 2010
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2010
Genentech Provides Update on FDA Application for T-DM1
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jul 2010
Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Jul 2010
Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jun 2010
Celgene to Acquire Abraxis BioScience Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Jun 2010
Data Show OrbusNeich's Genous Bio-engineered R stent is Safe and Effective in Combination with Drug-Eluting Balloon
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jun 2010
Cook Medical Files Pre-Market Approval Application for FDA Approval of Zilver(R) PTX(R) Drug-Eluting Stent Platform
Devices Interventional
 HSMN NewsFeed - 10 Jun 2010
Boston Scientific Announces European Launch and First Implants of Platinum Chromium TAXUS(R) Element Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Jun 2010
Spectranetics Plans Randomized Clinical Trial for In-Stent Restenosis
Devices Interventional
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2010
Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 25 May 2010
First Coronary Stent on Drug Eluting Balloon Implanted
Devices Interventional Cardiology
 HSMN NewsFeed - 20 May 2010
Boston Scientific Announces Schedule for EuroPCR 2010
Devices Interventional Cardiology
 HSMN NewsFeed - 12 May 2010
Boston Scientific Announces European Approval of Platinum Chromium TAXUS(R) Element(TM) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 6 May 2010
The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Apr 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Mar 2010
Boston Scientific Completes Enrollment in PLATINUM Trials for Small Vessels and Long Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2010
Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2010
PERSEUS Trial Results Demonstrate Positive Safety and Efficacy Outcomes for Boston Scientific's Novel Platinum Chromium TAXUS(R) Element(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Feb 2010
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2010
BSD Medical Reports Publication of Chinese Study Using the BSD-2000 Hyperthermia System to Treat Lung Cancer
Devices Oncology
 HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2010
Invatec Comments on First Clinical Results of Drug Eluting Balloon Technology for Below the Knee (BtK)
Devices Interventional
 HSMN NewsFeed - 28 Jan 2010
Abraxis BioScience Confirms Plan to Spin-off Abraxis Health in 2010 and Announces Management Structure
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2010
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2010
Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 7 Jan 2010
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2010
Boston Scientific Announces Enrollment of First Patient in Post-Approval Study for TAXUS Liberte Stent
Devices Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 1 Dec 2009
OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Nov 2009
Duke University Initiates Study of AEOL 10150 to Measure Compound's Ability to Protect Healthy Tissue in Mice Receiving Chemotherapy and Radiation for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Nov 2009
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Nov 2009
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Nov 2009
Boston Scientific Announces European Approval and Launch of Platinum Chromium PROMUS(R) Element(TM) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 29 Oct 2009
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Sep 2009
Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents Compared to Bare-Metal Stents in Heart Attack Patients at Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2009
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Sep 2009
TAXUS(R) Liberte(R) Stent Continues to Demonstrate Significant Improvements Over TAXUS(R) Express(R) Stent in Small Vessels and Long Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Sep 2009
New Zilver PTX Drug-Eluting Stent from Cook Medical Could Greatly Reduce Need for Leg Amputations and Bypass Surgery for European Patients
Devices Interventional
 HSMN NewsFeed - 18 Sep 2009
Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Sep 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 8 Sep 2009
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Sep 2009
OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study for OSI-906 in Adrenocortical Carcinoma and Phase I/II Study in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Sep 2009
Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Aug 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Aug 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Aug 2009
Breakthrough Drug-Eluting Stent to Treat Peripheral Arterial Disease Now Available in Europe
Devices Interventional
 HSMN NewsFeed - 11 Aug 2009
Zilver PTX Stent from Cook Medical Gains CE Mark
Devices Interventional Regulatory
 HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2009
FDA Approves Avastin for the Most Common Type of Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2009
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jul 2009
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jul 2009
FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 13 Jul 2009
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jun 2009
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2009
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 May 2009
FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
Boston Scientific Welcomes Launch of Syntax Score Website
Devices Cardiology
 HSMN NewsFeed - 19 May 2009
Invatec Receives CE Mark Approval for the IN.PACT Admiral Drug Eluting Balloon
Devices Interventional Regulatory
 HSMN NewsFeed - 19 May 2009
Invatec Officially Launches Coronary Drug-Eluting Balloon Platform IN.PACT Falcon at EuroPCR
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2009
Boston Scientific Announces Schedule for EuroPCR 2009
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2009
Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 7 May 2009
New Study Shows that Zilver PTX from Cook Medical Effectively Treats Blockages in Critical Thigh Artery
Devices Interventional
 HSMN NewsFeed - 5 May 2009
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2009
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Apr 2009
ARIAD Appoints Former Bristol-Myers Squibb Senior Executive as New Independent Member of Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Mar 2009
Boston Scientific Announces Schedule For ACC 2009
Devices Interventional Cardiology
 HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Mar 2009
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2009
FDA Appeal Decision Indicates that Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Trial
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Mar 2009
Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 18 Feb 2009
New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Feb 2009
Genta Submits Randomized Study of Tesetaxel in Patients with Advanced Gastric Cancer to FDA for Special Protocol Assessment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Feb 2009
Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Feb 2009
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2009
Abraxis BioScience Launches ABRAXANE in Germany
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2009
Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Jan 2009
Cook Medical unveils the Advance Drug-Eluting Balloon and Other Cutting-Edge Devices to Advance Leg Therapy at the ISET 2009 International Symposium on Endovascular Therapy
Devices Interventional
 HSMN NewsFeed - 29 Jan 2009
Angiotech's corporate partner, Boston Scientific, announces Japanese approval for TAXUS(R) Liberté(R) drug-eluting stent system
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 28 Jan 2009
Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Jan 2009
Boston Scientific Acquires Labcoat Limited
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 17 Dec 2008
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Nov 2008
Integrated BioPharma, Inc. Announces New Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Nov 2008
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2008
Abraxis BioScience and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in Australia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2008
TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated with Second-Generation TAXUS(R) Liberte(R) Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Oct 2008
Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Oct 2008
TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Oct 2008
Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Oct 2008
Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 8 Oct 2008
Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Sep 2008
Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 10 Sep 2008
Cook Medical Completes Enrollment in First International Trial of First-of-Its-Kind Drug-Eluting Peripheral Stent
Devices Interventional
 HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2008
TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Sep 2008
Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jul 2008
Medtronic Starts U.S. Arm of Global Study Comparing Safety of Endeavor(R) and Cypher(R) Drug-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Jul 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jul 2008
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jul 2008
Angiotech wins before the UK House of Lords
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 7 Jul 2008
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jul 2008
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 13 Jun 2008
Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
Devices
 HSMN NewsFeed - 11 Jun 2008
Interim Results for the Zilver(R) PTX(TM) Clinical Study from Cook Medical Show Promise for Improving the Treatment of Blockages in the Femoropopliteal Artery
Devices Interventional
 HSMN NewsFeed - 2 Jun 2008
Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 2 Jun 2008
ABRAXANE(R) in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Combination Therapy of Solvent-Free ABRAXANE(R) and the Targeted Therapy Bevacizumab Evaluated as First-Line Treatment for Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2008
TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2008
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 5 May 2008
European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 May 2008
Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
Devices FDA
 HSMN NewsFeed - 23 Apr 2008
Abraxis BioScience Reports Promising Clinical Data in Advanced Pancreatic Cancer Using a Combination of nab-Paclitaxel (ABRAXANE(R)) and Gemcitabine (Gemzar(R))
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2008
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Apr 2008
Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
Devices
 HSMN NewsFeed - 21 Apr 2008
Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2008
Angiotech's Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 Apr 2008
Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 Apr 2008
Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
Biopharmaceuticals Devices FDA
 HSMN NewsFeed - 11 Apr 2008
ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Apr 2008
Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
Devices Interventional
 HSMN NewsFeed - 2 Apr 2008
Genta Restructures Operations to Focus on Priority Initiatives
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2008
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Apr 2008
TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Apr 2008
Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
SPIRIT II Explores Long-Term Performance of XIENCE V Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
Acusphere Licenses Hydrophobic Drug Delivery System to Cephalon for $10 Million
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 29 Mar 2008
Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 29 Mar 2008
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 29 Mar 2008
TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Mar 2008
960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter
Devices Biopharmaceuticals
 HSMN NewsFeed - 18 Mar 2008
BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2008
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2008
Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Mar 2008
Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
Devices Licensing
 HSMN NewsFeed - 13 Mar 2008
Novelos Therapeutics Reaches Target Enrollment in Pivotal Phase 3 Lung Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2008
Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 11 Mar 2008
Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 7 Mar 2008
Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2008
Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 4 Mar 2008
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Feb 2008
FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2008
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 7 Feb 2008
Abraxis Bioscience Establishes Global Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2008
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
Devices Licensing
 HSMN NewsFeed - 1 Feb 2008
Abbott Gains Reimbursement for XIENCE(TM) V Drug Eluting Stent in France
Devices Reimbursement Interventional Cardiology
 HSMN NewsFeed - 28 Jan 2008
Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jan 2008
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Dec 2007
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2007
TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 18 Dec 2007
Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Dec 2007
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Dec 2007
Genentech Provides Update from Avastin FDA Advisory Meeting
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Nov 2007
Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE(TM) V Drug Eluting Stent to FDA Advisory Committee on Nov. 29
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Nov 2007
Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Abraxis BioScience Announces the Closing Date for the Separation of Its Proprietary Business from Its Hospital-Based Business
Biopharmaceuticals
 HSMN NewsFeed - 5 Nov 2007
Abbott Confirms FDA Advisory Panel to Review XIENCE(TM) V Drug Eluting Stent on November 29
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 2 Nov 2007
Acusphere to Develop Potential Abraxane(R) Bioequivalent
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 29 Oct 2007
European Symposium Focuses on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2007
Drug Eluting Balloons Show Promise as a Potential Alternative to Drug Eluting Stents Used in the Treatment of Coronary Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Oct 2007
AngioChem Announces IND Clearance From the US FDA for its Lead Product, ANG1005, for the Treatment of Brain Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Oct 2007
European Symposium on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2007
Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience Receives a Positive Opinion in Europe from the CHMP for the Approval of ABRAXANE for the Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2007
Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2007
ARIAD Announces Collaboration with ICON Medical to Develop and Commercialize Novel Deforolimus-Eluting Stents
Devices Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 10 Oct 2007
GlaxoSmithKline and Synta Pharmaceuticals Announce Development and Commercialization Collaboration for STA-4783 in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Oct 2007
Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
Devices FDA
 HSMN NewsFeed - 5 Oct 2007
Medtronic to Present Findings from the Comprehensive ENDEAVOR Clinical Experience to FDA Advisory Panel
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Sep 2007
Phase 3 Pivotal Trial of TOCOSOL(R) Paclitaxel Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2007
Pro-Pharmaceuticals Names Theodore Zucconi, Ph.D., President; Nominated to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2007
Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2007
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2007
Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
Devices Litigation Interventional Cardiology
 HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2007
Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Sep 2007
Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 2 Sep 2007
Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in World's Largest Stent Registry
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Aug 2007
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2007
Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
Devices Cardiology
 HSMN NewsFeed - 27 Aug 2007
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2007
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2007
Spectrum Pharmaceuticals Investigational New Drug Application for SPI-1620 Cleared by U.S. Food & Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2007
Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 25 Jul 2007
Spectrum Pharmaceuticals Acquires From Indena Worldwide Rights To Ortataxel, A Phase 2 Third Generation Taxane
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 25 Jul 2007
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 19 Jul 2007
Boston Scientific Announces First Implant of TAXUS(R) Element(TM) Platinum Chromium Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Jul 2007
Angiotech's corporate partner, Boston Scientific, announces first human use of TAXUS(R) Petal(TM) Bifurcation Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Jul 2007
Angiotech's corporate partner, Cook Medical, announces enrollment in pivotal study of paclitaxel-coated stent for use outside the heart
Devices Interventional
 HSMN NewsFeed - 17 Jul 2007
Boston Scientific Announces First Human Use of TAXUS(R) Petal(TM) Bifurcation Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Jul 2007
U.S. Patients Treated with New Drug-Coated Stent
Devices Interventional
 HSMN NewsFeed - 6 Jun 2007
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
XYOTAX(TM) More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE(R)) in Combination and as a Single Agent for the Treatment of Lung and Ovarian Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Positive Results for Second-Generation Taxus(R) Liberte(TM) Coronary Stent System Highlighted in Journal of American College of Cardiology
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Jun 2007
Pre-menopausal Estrogen Levels Linked to Higher Death Rate Among Women Receiving Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Telik Reports Results of TELCYTA(R) ASSIST-1 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Glaxosmithkline Reports Positive New Data on Tykerb(R)(Lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Xeloda(R) Plus Avastin(R) Combination Delays Disease Progression in Women with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2007
Abbott Submits XIENCE(TM) V Everolimus Eluting Coronary Stent System Application for U.S. FDA Approval
Devices Interventional Cardiology
 HSMN NewsFeed - 31 May 2007
OXiGENE Reaches Agreement with FDA on Special Protocol Assessment for ZYBRESTAT(TM) (CA4P) Phase II/III Pivotal Trial in Anaplastic Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 29 May 2007
Angiotech initiates European trial examining the Vascular Wrap(TM) paclitaxel-eluting mesh for Dialysis Patients with End-Stage Renal Disease
Devices
 HSMN NewsFeed - 24 May 2007
Boston Scientific Receives CE Mark for TAXUS(R) Liberte(TM) Long Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 22 May 2007
SPIRIT Clinical Data Reaffirm Strength of TAXUS(R) and PROMUS(TM) Drug-Eluting Coronary Stent Systems
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2007
Abbott Announces Continued Positive Results with XIENCE(TM) V Everolimus Eluting Coronary Stent in SPIRIT Clinical Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2007
ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2007
TAXUS VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2007
Boston Scientific Announces Schedule for EuroPcr 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 10 May 2007
Angiotech to market Vascular Wrap(TM)/ePTFE graft combination product through its own European sales and distribution networks
Devices Distribution
 HSMN NewsFeed - 8 May 2007
Boston Scientific Announces Japanese Launch of TAXUS(R) Express2(TM) Coronary Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 7 May 2007
Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions
Devices Interventional Cardiology
 HSMN NewsFeed - 3 May 2007
Integrated BioPharma to Explore Divesting Its Biotechnology Business
Biopharmaceuticals
 HSMN NewsFeed - 2 May 2007
Phyton Biotech Acquires Novel Glyco-Engineering Technology, Adds Enhanced Capacity to Manufacture Therapeutic Proteins
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 26 Apr 2007
Boston Scientific Announces Completion of Enrollment in Landmark Clinical Trial Comparing Drug-Eluting Stents To Cardiac Surgery
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Apr 2007
Two-year data for Angiotech's Vascular Wrap(TM) Paclitaxel-Eluting Mesh to be presented at European vascular symposium
Devices
 HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of TELCYTA as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
Biopharmacetuicals Oncology
 HSMN NewsFeed - 17 Apr 2007
Pro-Pharmaceuticals Issues Corporate Update
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2007
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Apr 2007
CINVENTION and Relisys Medical Devices Enroll First Patients in Clinical Trial of the Corel + C Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Apr 2007
Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and Commercial Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Apr 2007
Cell Therapeutics, Inc. (CTI) Announces XYOTAX(TM) Has Fast Track Designation for Women With Advanced Lung Cancer Who Are Performance Status 2 (PS2)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Apr 2007
Coley Pharmaceutical Group Announces Completion of Patient Enrollment in Pfizer's Two Pivotal Phase III NSCLC Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2007
Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Approval for the TAXUS(R) Express2(TM) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 3 Apr 2007
Boston Scientific Announces Japanese Approval for the TAXUS(R) Express2(TM) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 25 Mar 2007
Boston Scientific Reports Positive Two-Year Data From TAXUS V ISR Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Mar 2007
Boston Scientific Announces Results From Arrive 1 Registry Supporting Positive Performance of TAXUS(R) Stent System in Complex Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Spirit III Clinical Trial Demonstrates Positive Performance for Both TAXUS(R) and PROMUS(TM) Drug-Eluting Stent Systems
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Superior to TAXUS(R) Stent in SPIRIT III U.S. Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Mar 2007
Boston Scientific Announces Schedule for ACC 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Mar 2007
Cell Therapeutics Inc. (CTI) Files for Special Protocol Assessment (SPA) for XYOTAX(TM) PGT307 Lung Cancer Trial in Women
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Mar 2007
Angiotech Initiates U.S. Pivotal Trial for the Vascular Wrap(TM) Paclitaxel-Eluting Mesh
Devices Interventional
 HSMN NewsFeed - 5 Mar 2007
Boston Scientific to Provide Information to House Committee on Oversight and Government Reform
Devices Interventional Cardiology
 HSMN NewsFeed - 28 Feb 2007
Pro-Pharmaceuticals Submits Orphan Drug Status Application to European Medicines Agency Co-administration of DAVANAT(R) with 5-FU to Treat Cholangiocarcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Feb 2007
'Encouraging' Major Responses Seen With XYOTAX(TM) in Patients With Taxane-Resistant Androgen Independent Prostate Cancer
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2007
Conor Medsystems to Present COSTAR II Data at EuroPCR
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Feb 2007
Pro-Pharmaceuticals Meeting Scheduled with the FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2007
Valeant Pharmaceuticals Files Investigational New Drug Application for Cesamet(R) in Cancer Chemotherapy-Induced Neuropathic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Feb 2007
Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2007
Boston Scientific Comments on Swedish Registry Results
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Feb 2007
Boston Scientific Welcomes New England Journal of Medicine Articles on Drug-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 7 Feb 2007
Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2007
Abbott to Initiate First Study to Evaluate XIENCE(TM) V Everolimus Eluting Coronary Stent System in Treatment of Women With Cardiovascular Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Jan 2007
First International Trial of Drug-Eluting Peripheral Artery Stent Results Encouraging
Devices Interventional
 HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jan 2007
Safety Monitoring Board Recommends Continuation of EntreMed's MKC-1 Phase 2 Breast Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jan 2007
FDA Approves 18-Month Shelf Life for TAXUS(R) Stent System
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 17 Jan 2007
Angiotech wins patent infringement case in the Netherlands
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 17 Jan 2007
Boston Scientific and Angiotech Win Patent Infringement Case Against Conor in the Netherlands
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 16 Jan 2007
Conor Medsystems Announces Decision From U.K. Court of Appeal
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 16 Jan 2007
Boston Scientific Comments on U.K. Court Decision on Angiotech Patent
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 16 Jan 2007
UK Court of Appeal releases decision on Angiotech patent
Devices Biopharmaceuticals Cardiology Litigation
 HSMN NewsFeed - 12 Jan 2007
Study in European Heart Journal Favors TAXUS(R) Stent Over Cypher(R) Stent and Bare-Metal Stents in Diabetic Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jan 2007
Private-Label Version of Abbott's XIENCE(TM)V Drug-Eluting Coronary Stent System Launches in Europe
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jan 2007
Boston Scientific Announces First Use of PROMUS(TM) Everolimus-Eluting Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Jan 2007
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare Conference
Biopharmaceuticals
 HSMN NewsFeed - 27 Dec 2006
OXiGENE Announces Positive Results of Phase II Study of Combretastatin (CA4P) in Combination with Paclitaxel and Carboplatin in Patients with Advanced Imageable Malignancies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Dec 2006
Company Announces Acquisition of Research and Development Programs, Hiring of Senior Management Team and Name Change
Biopharmaceuticals Acquisitions Personnel
 HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Dec 2006
Xeloda(R) Plus Avastin(R) Combination May Produce Clinical Benefit in Patients with Advanced Breast Cancer
Biopharmaceuticaals Oncology
 HSMN NewsFeed - 15 Dec 2006
Lipoxen Announces $75M Agreement With Baxter to Develop New Blood Clotting Factors
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 14 Dec 2006
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2006
CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101) Clinical Trial in Cutaneous T-cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2006
Real-World Taxus(R) Stent Data Confirm Favorable Outcomes for Patients With Complex Coronary Artery Disease
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 7 Dec 2006
Data Presented To FDA Panel Show TAXUS Drug-Eluting Stents as Safe as Bare-Metal Stents and Far More Effective in Reducing Repeat Procedures
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
Cleveland Clinic Analysis Finds Patients With Drug-Eluting Stents Are at Increased Risk for Late Thrombosis
Devices Interventional Cardiology
 HSMN NewsFeed - 29 Nov 2006
Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane(R) and Temodar(R) as First-Line Therapy for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Nov 2006
SurModics Provides Additional Information on its License Agreement with Conor Medsystems
Devices Interventional Cardiology Licensing
 HSMN NewsFeed - 16 Nov 2006
Johnson & Johnson Announces Definitive Agreement to Acquire Conor Medsystems, Inc.
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Nov 2006
Sonus Pharmaceuticals Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of TOCOSOL(R) Paclitaxel in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2006
Angiotech submits application for European regulatory approval for its Vascular Wrap(TM) product
Devices Drug Delivery Regulatory
 HSMN NewsFeed - 16 Nov 2006
CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial of PXD101 for Myelodysplastic Syndrome
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Nov 2006
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Nov 2006
Boston Scientific and University of Akron Expand License Agreement for Use of UA Polymers in Medical Devices
Devices Cardiology Licensing
 HSMN NewsFeed - 14 Nov 2006
Study Favors TAXUS(R) Stent Over Cypher(R) Stent and Bare-Metal Stents in Diabetic Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Nov 2006
Angiotech's Vascular Wrap(TM) trial results demonstrate reduced incidence of amputation
Devices
 HSMN NewsFeed - 8 Nov 2006
Use of Hyperthermia Therapy in Treating Primary and Recurrent Breast Cancer Highlights Breast Cancer Congress
Devices Oncology
 HSMN NewsFeed - 6 Nov 2006
Mayne Pharma (USA) Inc. Announces the Launch of Epirubicin Hydrochloride for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2006
Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemoradiotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2006
TAXUS Long-Term Data Excels in Diabetic Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Nov 2006
Clinical Studies to be Presented at American Heart Association Scientific Sessions Demonstrate Growing Body of Efficacy and Safety Data for the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
Return to NewsFeed  

 Additional items found! 500

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 500 additional stories matching:
Paclitaxel
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.